Home | Welcome to Contract Pharma   
Last Updated Monday, November 24 2014
Print RSS Feed

Financial Report: Alkermes



By Kristin Brooks



Published February 27, 2014
Alkermes

3Q Revenues: $154.5 million (+14%)

3Q Earnings: $18.1 million (+11%)

YTD Revenues: $432.9 million (+5%)

YTD Earnings: $17.6 million (-20%)

Comments: Manufacturing and royalty revenues in the quarter were $132.7 million, up 12%, driven by the atypical antipsychotic franchise, up 36% to $71.2 million. Product sales were $20.6 million, up 29% driven by and VIVITROL, with sales up 30% to $20.6 million. R&D revenues were $1.2 million, down 31%.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On